Arthur Brothag is Apax's Global Head of Development and Partner in the Investor Relations Team. He was promoted to this role in 2022 to oversee business development and strategy for Apax and serve as a key point of contact for investors.
Prior to this, Arthur was a Partner in Apax's healthcare investment team, and between 2009 and 2021 worked on deals including Acelity, Neuraxpharm, Rodenstock, TietoEVRY, Unilabs and Vyaire Medical.
Before joining Apax, Arthur worked as an investor at the private equity firm Warburg Pincus, as well as at Morgan Stanley Investment Banking. Arthur originally trained as a medical doctor at the Technical University of Munich, where he also did his doctoral research. He held resident doctor positions in Germany and Switzerland in cardiology and oncology. He later completed his MBA studies with distinction at INSEAD.
Arthur holds/has held Board memberships of Rodenstock, Acelity (KCI), Neuraxpharm, Unilabs and Vyaire Medical.
After more than 15 years on the investment side, primarily in healthcare at Apax, Arthur is excited to now be working on the firm’s overall strategy and making this as attractive as possible to Apax's investors. During his time in the healthcare team, Arthur often helped investors better understand Apax’s edge and shared insights into the transactions he worked on. Focusing on what it is that defines the firm, while building strong relationships with both present and future investors is therefore something that he naturally feels an affinity to. Arthur's new role builds on the perspectives he gained during his previous work on investments. Arthur believes strongly that the relationship between Apax and the Apax Funds' investors is symbiotic, and that the firm’s role in wealth generation mutually benefits institutional investors and their ultimate beneficiaries, be they someone saving for retirement, putting children through school, or managing funds for a charity.